Windlas Biotech Limited
Windlas Biotech Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 2001, the company has established itself as a leader in the development and manufacturing of high-quality generic formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. With a strong focus on innovation, Windlas Biotech offers a diverse portfolio of products that cater to multiple therapeutic segments, including cardiovascular, anti-diabetic, and anti-infective medications. The company is recognised for its state-of-the-art manufacturing facilities, which adhere to stringent international quality standards. Windlas Biotech has achieved significant milestones, including regulatory approvals from global health authorities, positioning itself as a trusted partner in the pharmaceutical supply chain. Its commitment to quality and sustainability has solidified its reputation in the competitive biotech landscape.
DitchCarbon Score
How does Windlas Biotech Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Windlas Biotech Limited's score of 16 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Windlas Biotech Limited's reported carbon emissions
Windlas Biotech Limited, headquartered in India, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or climate commitments outlined in their initiatives. Without concrete figures or commitments, it is challenging to assess their carbon footprint or climate strategy. However, the absence of data may indicate an opportunity for the company to enhance transparency and set measurable climate goals in line with industry standards. As the pharmaceutical sector increasingly prioritises sustainability, Windlas Biotech may benefit from establishing clear emissions reduction targets and engaging in climate pledges to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Windlas Biotech Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
